Revenues at Pharmaceutical Product Development (Nasdaq: PPDI) grew more than 7 percent from a year ago in the third quarter, the life science services company reported Wednesday.

Revenues rose to $365.4 million for the quarter.

The profit of 32 cents per share matched the 2009 quarterly total.

“Gross authorizations continued to be strong, and operating margin expanded significantly on a sequential basis due to improved performance in emerging markets and our focus on overall company spending,” said PPD Chief Executive Officer David Grange in a statement.

For the full report,

Get the latest news alerts: at Twitter.